Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Apr 20, 2024 1:21pm
141 Views
Post# 35999606

RE:clinical trials

RE:clinical trialsGreat details on the in place studies.
All with the same goal. To get Pelareorep to market , to improve people's lives.
Absolutely there are more.
My point was from an outcome point of view, the are millions of people/ year that will benifit.
Each trial for example involves the patients directly, their families. Also involved hoping for success the hundreds of health care workers & scientists involved.
Only a very few of shorters & bashers would be happy to see Onc fail.
With the recent FDA meeting request for phase 3 discussions, & the focus on increasing production, clearly the end goal is much closer.
The most clinical significant results lately , the pancreatic cancer trail with a Roche lead cancer drug tecentriq.
agreed 100%, the others that we know of.
pfizer, Incyte, Bms,  and a very important biomarker lab company , name I forget. They were brought in  to help with the bio- details in the Aware-1, study.
They are using technology not avaible 5 years ago.
it is that very technology & markers they are discussing with FDA.
If accepted, they will be able to tune the trial , very early.
AkA after only 2 weeks a simple blood draw will indicate if Pela will work for the individual or not.
For those with the desire. Take a deeper dive into Pelareorep as a cancer treatment.
No deal yet?
Mangement is saying multi billions, larger pharm saying let's see the data first.
The FDA meeting request & potential outcomes, could set up a wonderful opportunity.
Safe weekend all.
regards

<< Previous
Bullboard Posts
Next >>